Is BJURF or MRK a better dividend investment in 2026?

BJURF currently yields 334.28% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: BJURF offers higher current income.

What is the dividend yield difference between BJURF and MRK?

BJURF has a forward dividend yield of 334.28% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 331.52 percentage points.

Home › Compare › BJURF vs MRK

BJURF vs MRK: Dividend Comparison 2026

BJURF yields 334.28% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 BJURF wins by $3174.22M in total portfolio value

INVESTMENT

TIME HORIZON10 years

BJURF

● Live price

334.28%

Share price

$0.60

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$3174.27M

Annual income

$1,998,316,749.42

Full BJURF calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — BJURF vs MRK

📍 BJURF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BJURF	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BJURF + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BJURF pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BJURF

Annual income on $10K today (after 15% tax)

$28,413.84/yr

After 10yr DRIP, annual income (after tax)

$1,698,569,237.01/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, BJURF beats the other by $1,698,560,908.60/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BJURF + MRK for your $10,000?

BJURF: 50%MRK: 50%

100% MRK50/50100% BJURF

Portfolio after 10yr

$1587.16M

Annual income

$999,163,273.78/yr

Blended yield

62.95%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

BJURF

No analyst data

Altman Z

4.6

Piotroski

4/9

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BJURF buys

MRK buys

No recent congressional trades found for BJURF or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBJURFMRK

Forward yield	334.28% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$3174.27M ✓	$56.8K
Annual income after 10y	$1,998,316,749.42 ✓	$9,798.13
Total dividends collected	$3060.29M ✓	$28.9K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: BJURF vs MRK ($10,000, DRIP)

Year	BJURF Portfolio	BJURF Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$44,128	$33,428.05	$11,206	$366.19	+$32.9K → BJURF
2	$185,078	$137,861.16	$12,650	$502.35	+$172.4K → BJURF
3	$738,413	$540,379.20	$14,407	$694.19	+$724.0K → BJURF
4	$2,805,027	$2,014,925.05	$16,585	$967.82	+$2.79M → BJURF
5	$10,154,785	$7,153,406.32	$19,342	$1,363.89	+$10.14M → BJURF
6	$35,068,265	$24,202,645.29	$22,913	$1,947.19	+$35.05M → BJURF
7	$115,635,916	$78,112,872.55	$27,662	$2,823.89	+$115.61M → BJURF
8	$364,453,269	$240,722,838.19	$34,159	$4,173.35	+$364.42M → BJURF
9	$1,099,024,401	$709,059,403.47	$43,337	$6,308.80	+$1098.98M → BJURF
10	$3,174,272,858	$1,998,316,749.42	$56,776	$9,798.13	+$3174.22M → BJURF

BJURF vs MRK: Complete Analysis 2026

BJURF — Stock

Bonjour Holdings Limited, an investment holding company, engages in the retail and wholesale of beauty and health-care products in Hong Kong, Macau, and the Mainland China. The company offers skin, health food, and hair and body care products; and cosmetics and fragrance products, as well as lifestyle products and snacks from Japan, Korea, and Taiwan to cater to customers' various needs. As of December 31, 2020, it operated 24 retail stores in Hong Kong and Macau. The company also sells its products online. In addition, it is involved in the property holding activities. The company was founded in 1991 and is headquartered in Tsuen Wan, Hong Kong.

Full BJURF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this BJURF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BJURF vs SCHD BJURF vs JEPI BJURF vs O BJURF vs KO BJURF vs MAIN BJURF vs JNJ BJURF vs ABBV BJURF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.